SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $572,100 | -74.1% | 15,000 | -78.1% | 0.08% | -68.1% |
| Q2 2022 | $2,213,000 | +57.3% | 68,500 | +61.2% | 0.26% | +550.0% |
| Q1 2022 | $1,407,000 | -84.1% | 42,500 | -79.6% | 0.04% | -77.9% |
| Q4 2021 | $8,870,000 | +39.5% | 208,500 | +45.3% | 0.18% | -6.2% |
| Q3 2021 | $6,358,000 | -2.6% | 143,500 | +24.9% | 0.19% | -16.8% |
| Q2 2021 | $6,527,000 | -62.0% | 114,900 | -49.9% | 0.23% | -45.9% |
| Q1 2021 | $17,155,000 | +5877.4% | 229,200 | +7540.0% | 0.43% | +479.7% |
| Q4 2018 | $287,000 | – | 3,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |